HomeCompareAKSJF vs ABBV

AKSJF vs ABBV: Dividend Comparison 2026

AKSJF yields 1345.42% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKSJF wins by $261992149.80M in total portfolio value
10 years
AKSJF
AKSJF
● Live price
1345.42%
Share price
$2.95
Annual div
$39.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$261992149.90M
Annual income
$228,572,448,613,362.30
Full AKSJF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AKSJF vs ABBV

📍 AKSJF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKSJFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKSJF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKSJF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKSJF
Annual income on $10K today (after 15% tax)
$114,361.02/yr
After 10yr DRIP, annual income (after tax)
$194,286,581,321,357.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AKSJF beats the other by $194,286,581,300,301.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKSJF + ABBV for your $10,000?

AKSJF: 50%ABBV: 50%
100% ABBV50/50100% AKSJF
Portfolio after 10yr
$130996075.00M
Annual income
$114,286,224,319,067.03/yr
Blended yield
87.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AKSJF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKSJF buys
0
ABBV buys
0
No recent congressional trades found for AKSJF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKSJFABBV
Forward yield1345.42%3.06%
Annual dividend / share$39.69$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$261992149.90M$102.3K
Annual income after 10y$228,572,448,613,362.30$24,771.77
Total dividends collected$259531317.43M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AKSJF vs ABBV ($10,000, DRIP)

YearAKSJF PortfolioAKSJF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$145,242$134,542.38$11,550$430.00+$133.7KAKSJF
2$1,981,695$1,826,285.46$13,472$627.96+$1.97MAKSJF
3$25,408,205$23,287,791.77$15,906$926.08+$25.39MAKSJF
4$306,236,601$279,049,821.60$19,071$1,382.55+$306.22MAKSJF
5$3,470,938,760$3,143,265,596.63$23,302$2,095.81+$3470.92MAKSJF
6$37,009,528,330$33,295,623,856.57$29,150$3,237.93+$37009.50MAKSJF
7$371,395,302,942$331,795,107,629.62$37,536$5,121.41+$371395.27MAKSJF
8$3,509,174,205,017$3,111,781,230,868.68$50,079$8,338.38+$3509174.15MAKSJF
9$31,233,365,687,823$27,478,549,288,455.11$69,753$14,065.80+$31233365.62MAKSJF
10$261,992,149,899,333$228,572,448,613,362.30$102,337$24,771.77+$261992149.80MAKSJF

AKSJF vs ABBV: Complete Analysis 2026

AKSJFStock

Sberbank of Russia, together with its subsidiaries, provides corporate and retail banking products and services to individuals, small businesses, corporate clients, and financial institutions. The company offers deposit products; pension accounts; payment, transfer, brokerage, and asset management services; car, housing, education, and consumer loans; mortgages; debit and credit cards, and overdraft service; and refinancing products. It also provides derivative, financial instrument, foreign currency, precious metal, corporate structured, and commodities and securities products, as well as debt and capital markets funding, documentary, and other commission services. In addition, it offers life, property, bank card, accident, liability, trust management, investment and universal life, travel, and mutual investment funds insurance products, as well as individual pension plans and corporate pension programs. Additionally, the company provides business bank accounts, platform for exporters and importers, merchant acquiring and international trading services, and corporate cards for small businesses; and loans, investment products and capital markets services, fund investment services, and banking services for corporate clients. It also provides trade finance, interbank lending, currency risk hedging, and treasury services; deposits, custody services, and electronic trading systems; and settlement and cash collection services to financial institutions. As of December 31, 2020, the company operated 11 Regional banks and 14,162 branches in Russia. The company also has operations in 18 countries internationally. Sberbank of Russia was founded in 1841 and is headquartered in Moscow, Russia.

Full AKSJF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AKSJF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKSJF vs SCHDAKSJF vs JEPIAKSJF vs OAKSJF vs KOAKSJF vs MAINAKSJF vs JNJAKSJF vs MRKAKSJF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.